Literature DB >> 11783156

[Clinical observation of the effect of shuxinsu capsule in treating angina pectoris].

H Li1, L Cui, W Zhou.   

Abstract

OBJECTIVE: To observe the therapeutic effect of Shuxinsu capsule (SXSC) in treating angina pectoris patients.
METHODS: One hundred and fifty angina pectoris patients were divided into two groups. Group A (80 cases), randomly divided into two subgroups, SXSC treated and Yixin oral liquid (YXOL) control group, each group consisted of 40 cases. Group B (70 cases) was an openly treated group (OTG).
RESULTS: 17 cases were markedly effective in the SXSC treated group in relieving the symptoms, effective were 16, the total effective rate was 82.50%, while in the control group, the markedly effective cases, the effective cases and the total effective rate were 13, 16 and 72.50% respectively; there was significant difference between these two groups (u = 1.99, P < 0.05). In the treated group (SXSC and OTG) of 110 cases, the markedly effective, effective cases on ECG were 34 and 30 respectively. The total effective rate was 58.18%, higher than that of the control group, which was 55.00%, but the difference was insignificant. The activity of SOD in RBC and the amount of plasma LPO were significantly different after treatment in the SXSC group. Both of the medications had effect to reduce serum total cholesterol (TC) and triglyceride (TG), the TC was lower and high density lipoprotein-cholesterol (HDL-C) higher significantly after treatment in the SXSC group.
CONCLUSION: SXSC has significant effect on angina pectoris.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11783156

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  1 in total

1.  Qualitative analysis of xinyue capsules by high-performance liquid chromatography: Preliminary evaluation of drug quality in a Sino-Austrian joint study.

Authors:  Mei Xue; Lin Yang; Da-zhuo Shi; Christian Radauer; Heimo Breiteneder; Yan Ma
Journal:  Chin J Integr Med       Date:  2015-11-03       Impact factor: 1.978

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.